Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BNT112 |
Synonyms | |
Therapy Description |
BNT112 is an mRNA-based cancer vaccine that encodes prostate cancer antigens, which may activates anti-tumor immune response (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BNT112 | BNT 112|BNT-112|W_pro1 | BNT112 is an mRNA-based cancer vaccine that encodes prostate cancer antigens, which may activates anti-tumor immune response (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04382898 | Phase Ib/II | BNT112 + Cemiplimab BNT112 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT) | Terminated | USA | HUN | GBR | DEU | 0 |